Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II regorafenib monotherapy in first-line KIT/PDGFR wild-type metastatic or unresectable GIST
2015-001048-12Phase 2Active
- Sponsor
- GE Information Services
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in gastrointestinal stromal tumor (GIST), sponsored by GE Information Services. Primary endpoints: Disease Control Rate (DCR) and RECIST response evaluation. Started Jul 2015; status: active.
02
Drugs
regorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2015-001048-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001048-12.